Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant
- Vibrato Medical
MONTIRVINE, Calif.–(BUSINESS WIRE)–Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that it has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA, and has also received a $1.5M National Institutes of Health (NIH) grant. Together, funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of PAD, from the convenience of their home. Read more…
Related Reading
Event / Regulatory Affairs
Pulse on MedTech: How the Industry is Reigniting Growth and Expanding Markets
April 30, 2026
11:00 AM – 12:00 PM
Join Ernst & Young LLP in this session that explores key trends shaping the sector.
Event / Regulatory Affairs
The UPC – Three Years In Cross-Border Medtech Patent Strategy in the New European Landscape
April 28, 2026
1:00 PM – 2:00 PM
Join McDermott Will & Schulte Law in this session that will explore practical, cross-border patent litigation strategies for navigating the UPC system specifically for the medtech sector.
Event / Regulatory Affairs
The State of the MedTech Customer Base
May 7, 2026
1:00 PM – 2:00 PM
Join L.E.K. Consulting to explore hospital financial health, purchasing behavior, and strategic priorities, and what they mean for medtech growth, partnerships, and innovation.
Event / Regulatory Affairs
Beyond the Silo: Why Fragmentation Is MedTech’s Biggest Threat
May 6, 2026
12:00 PM – 1:00 PM
Discover how Salesforce is helping medtech organizations improve margins and scale with AI powered, connected enterprise platforms.
Event / Regulatory Affairs
FDA For-Cause Inspections Targeting Medical Device Manufacturers: Navigating the Process, Mitigating Risks
April 13, 2026
10:00 AM – 11:00 AM
Join Hogan Lovells in this webinar will examine FDA for-cause inspections as they relate to medical device manufacturers.
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Welcomes House Passage of Legislation Restoring Programs That Jumpstart Early-stage Medtech Innovation
March 17, 2026
WASHINGTON—AdvaMed, the Medtech Association, today applauded House of Representatives passage of S. 3971, the Small Business Innovation and Economic Security Act, legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. House passage follows Senate passage earlier this month, bringing the restoration of these initiatives one step closer to completion.
News / Business Development / Small Business
AdvaMed® Welcomes Senate Passage of Legislation Restoring Programs That Jumpstart Early Stage Medtech Innovation
March 4, 2026
WASHINGTON—AdvaMed, the Medtech Association, today welcomed Senate approval of legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and urged the House of Representatives to act swiftly on passage.
News / Radiation Therapy / Small Business
ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
February 26, 2026
HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the completion of patient enrollment in its pivotal U.S. FDA Investigational Device Exemption (IDE) study, ROUTE90. The study evaluates Eye90 microspheres®, a novel Yttrium-90 (Y90) radioembolization device, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.